Decades of CKD dietary guidance centered on restricting protein, potassium, and phosphorus has paradoxically discouraged fruit and vegetable consumption — directly contradicting updated nephrology guidelines that now endorse Mediterranean and plant-forward eating patterns. The authors argue that registered dietitian nutritionists (RDNs) delivering formal medical nutrition therapy (MNT) — encompassing comprehensive assessment of labs, medications, food access, and behavioral counseling — should be standard of care for all CKD patients, with particular urgency for those experiencing protein-energy wasting, pursuing conservative kidney failure management, or using GLP-1/GIP agonists whose anorexic effects risk inadequate protein and micronutrient intake.
This perspective reframes CKD nutrition from a restriction model to a diet-quality model, aligning nephrology with broader chronic disease evidence showing Mediterranean-pattern diets reduce cardiovascular mortality and slow metabolic decline. The GLP-1 drug angle is timely: as semaglutide and tirzepatide gain traction in CKD-adjacent obesity and diabetes management, the risk of sarcopenic weight loss in already-vulnerable kidney patients is a genuine clinical blind spot that MNT is uniquely positioned to address. The core indictment — that MNT is fully covered by Medicare and most US insurers yet remains chronically underutilized — points to a systemic referral failure rather than a resource gap. As opinion rather than primary data, this piece carries no effect sizes or cohort evidence, but its clinical reasoning is well-grounded and actionable. For patients with stage 3–5 CKD, advocating for an RDN referral may be one of the highest-yield, lowest-barrier interventions currently available.